Picture of Progyny logo

PGNY — Progyny News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapSuper Stock

Progyny Q1 revenue slightly beats estimates, raises FY outlook

Overview

US women's health benefits provider's Q1 revenue rose slightly, slightly beating analyst expectations

Adjusted EPS and adjusted EBITDA for Q1 beat analyst expectations

Company completed $200 mln share buyback, repurchasing 8.8 mln shares since November

Outlook

Progyny sees Q2 revenue between $342 mln and $355 mln

Company expects full-year 2026 revenue of $1.365 bln to $1.405 bln

Progyny says guidance reflects variability in member engagement and macroeconomic uncertainty

Result Drivers

CLIENT GROWTH OFFSET BY LOST ACCOUNT - Co said revenue growth was driven by an increase in clients and covered lives, but was largely offset by the loss of a large client that did not renew for 2025

EFFICIENCY GAINS - Higher gross profit and margin reflected ongoing efficiencies in care management and lower stock-based compensation expense

ROBUST DEMAND - Early selling season activity and higher member engagement reflected strong demand for women's health and family building solutions

Company press release: ID:nGNX3yz9rP

Key Details

MetricBeat/MissActualConsensus Estimate
Q1 RevenueSlight Beat*$328.50 mln$326.57 mln (9 Analysts)
Q1 Adjusted EPSBeat$0.50$0.30 (9 Analysts)
Q1 EPS$0.29
Q1 Net Income$24.23 mln
Q1 Adjusted EBITDABeat$56.58 mln$53.31 mln (10 Analysts)
Q1 Gross Profit$83.07 mln
Q1 Pretax Profit$36.88 mln
*Applies to a deviation of less than 1%; not applicable for per-share numbers. Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell" The average consensus recommendation for the managed healthcare peer group is "buy" Wall Street's median 12-month price target for Progyny Inc is $28.00, about 49.7% above its May 6 closing price of $18.70 The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 26 three months ago For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Progyny

See all news